Skip to content
Search

Latest Stories

After KGF Chapter 2, Hombale Films' Kantara takes box office by storm

The film, starring Rishab Shetty and Kishore, has received rave reviews with critics praising the production values.

After KGF Chapter 2, Hombale Films' Kantara takes box office by storm

The highly anticipated film Kantara from the house of Hombale Films has been released and is currently enjoying a successful run in the theatres.

Released on 30th September 2022, Kantara is a story of a mysterious forest and major happenings surrounding the area. This is after KGF’s mega-success that yet another Hombale production is enjoying a victory at the box office.


Today, taking to social media, BookMyShow shared a post highlighting the success of Kantara as the film received a record-breaking 99% rating with 18k+ reviews. This is the first time in the history of BookMyShow that a film has marked such a rating. In the caption, they wrote “The grandeur and magic of #Kantara is undeniable! Catch this blockbuster in theatres near you!

Directed by Rishab Shetty, and produced by Vijay Kiraganduru, Kantara stars a talented cast of Rishabh Shetty and Sapthami Gowda in the lead. The film is rooted in a vibrant setting and it is performed with utmost perfection. There are moments that leave you in goosebumps.

Hombale Films emerged as a pan-India brand with KGF, which opened to a good response at the box office in 2018. The banner consolidated its standing earlier this year with KGF Chapter 2. The Yash-led film proved to be a blockbuster and opened new avenues for Kannada cinema. The banner is also behind Salaar, starring Prabhas and Shruti Haasan.

Hombale Films' latest offering, Kantara, opened in cinemas on Friday, September 30. The film, starring Rishab Shetty and Kishore, has received rave reviews with critics praising the production values.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less